LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Home・Elenco Azioni・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

20.16 4.08

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

19.36

Massimo

20.33

Metriche Chiave
By Trading Economics
Entrata	25M -43M
Vendite	-3.6M 65M
EPS	-0.48
Margine di Profitto	-65.788
Dipendenti	298
EBITDA	-16M -31M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+106.15% upside

Dividendi
By Dow Jones
Utili prossimi	3 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-149M 1.7B
Apertura precedente	16.08
Chiusura precedente	20.16

Notizie sul Sentiment di mercato

By Acuity

100%

329 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

9.91 / 14.15 Supporto e resistenza

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 mag 2026, 20:36 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mag 2026, 23:28 UTC

Discorsi di Mercato

Utili

Global Forex and Fixed Income Roundup: Market Talk

19 mag 2026, 23:28 UTC

Discorsi di Mercato

Utili

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mag 2026, 23:10 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

19 mag 2026, 23:10 UTC

Discorsi di Mercato

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mag 2026, 22:02 UTC

Utili

ZTO Express (Cayman): Di Xu to Resign From Board

19 mag 2026, 22:01 UTC

Utili

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mag 2026, 22:01 UTC

Utili

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mag 2026, 22:00 UTC

Utili

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mag 2026, 21:37 UTC

Utili

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mag 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mag 2026, 21:01 UTC

Utili

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mag 2026, 20:58 UTC

Utili

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mag 2026, 20:46 UTC

Azioni calde

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mag 2026, 20:43 UTC

Discorsi di Mercato

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mag 2026, 20:34 UTC

Utili

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries 4Q EPS 5c >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries 4Q Sales $1.4B >JHX

19 mag 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mag 2026, 20:18 UTC

Discorsi di Mercato

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mag 2026, 20:13 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

19 mag 2026, 20:13 UTC

Discorsi di Mercato

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mag 2026, 20:03 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mag 2026, 20:03 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mag 2026, 20:02 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mag 2026, 20:02 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mag 2026, 19:23 UTC

Discorsi di Mercato

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

106.15% in crescita

Previsioni per 12 mesi

Media 39.91 USD 106.15%

Alto 57 USD

Basso 29 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

9.91 / 14.15Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

329 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.